ELGN-2112

· Elgan Pharma Ltd.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for ELGN-2112, covering 2026-01-23 to 2026-04-09. Get the full timeline:

Most recent: Clinical Trial Update: Assess the Safety of ELGN-2112 in Preterm Infants Born Under 26 Weeks GA and IUGR Infants Born 26-32 Weeks GA [Phase 2]

See pricing